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To identify the clinical phenotypes and infectious triggers in the 2019 Peruvian Guillain-Barré
syndrome (GBS) outbreak.
Methods
We prospectively collected clinical and neurophysiologic data of patients with GBS admitted to
a tertiary hospital in Lima, Peru, between May and August 2019. Molecular, immunologic, and
microbiological methods were used to identify causative infectious agents. Sera from 41 con-
trols were compared with cases for antibodies to Campylobacter jejuni and gangliosides. Ge-
nomic analysis was performed on 4 C jejuni isolates.
Results
The 49 included patients had a median age of 44 years (interquartile range [IQR] 30–54 years),
and 28 (57%) were male. Thirty-two (65%) had symptoms of a preceding infection: 24 (49%)
diarrhea and 13 (27%) upper respiratory tract infection. Themedian time between infectious to
neurologic symptoms was 3 days (IQR 2–9 days). Eighty percent had a pure motor form of
GBS, 21 (43%) had the axonal electrophysiologic subtype, and 18% the demyelinating subtype.
Evidence of recent C jejuni infection was found in 28/43 (65%). No evidence of recent
arbovirus infection was found. Twenty-three cases vs 11 controls (OR 3.3, confidence interval
[CI] 95% 1.2–9.2, p < 0.01) had IgM and/or IgA antibodies against C jejuni. Anti-GM1:
phosphatidylserine and/or anti-GT1a:GM1 heteromeric complex antibodies were strongly
positive in cases (92.9% sensitivity and 68.3% specificity). Genomic analysis showed that the C
jejuni strains were closely related and had the Asn51 polymorphism at cstII gene.
Conclusions
Our study indicates that the 2019 Peruvian GBS outbreak was associated with C jejuni infection
and that the C jejuni strains linked to GBS circulate widely in different parts of the world.
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Guillain-Barré syndrome (GBS) is an immune-mediated
disorder frequently triggered by infections, characterized by
an acute flaccid paralysis, accompanied by sensory symptoms
and cranial nerve deficits.1 In recent years, several outbreaks of
GBS have been observed globally, including the large out-
breaks in Latin America during the Zika virus (ZIKV)
epidemic,2–4 and the possibility of an association between
severe acute respiratory syndrome coronavirus 2 infection and
GBS has been raised.5 As the ZIKV epidemic transitioned to
an endemic phase in the Americas in 2017, 2 major outbreaks
of GBS occurred in Peru in 2018 and 2019. The number of
reported GBS cases increased from 59 in 2017 (incidence:
0.19/100,000) to 262 in 2018 (incidence: 0.81/100,000) and
1,120 in 2019 (incidence: 3.44/100,000).6 During these
outbreaks, the increases in GBS cases were also reported in
areas where there is no potential arboviral transmission, such
as the highlands of Peru. The outbreaks had a seasonal pattern
with the major peaks occurring between April and July in both
years (figure 1A).6,7 We investigated the causality of these
outbreaks, by performing an observational clinical cohort
study of adult patients with GBS evaluated at a tertiary uni-
versity hospital in Lima during the 2019 outbreak.
Methods
Study Population and Design
We prospectively evaluated the clinical and laboratory fea-
tures of patients suspected of GBS at the Hospital Cayetano
Heredia (HCH), a university-based tertiary care hospital in
Lima, Peru, during the 2019 GBS outbreak (May–August) in
Peru. We included all patients who were evaluated by a
neurologist and fulfilled the Brighton Collaboration Working
Group criteria for diagnosis of GBS with a classification level
1, 2, or 3.8 Included patients underwent neurologic evaluation
during the acute and convalescent phase of their illness and
were followed up to 6 months after discharge. Patients with
alternative diagnoses or insufficient data were excluded.
Blood, CSF, respiratory, and stool samples were obtained
during the acute phase as part of the standard of care to
identify potential infectious etiologies. Nerve conduction
studies (NCSs) and EMG were performed and classified
according to the criteria of Hadden et al.9,10 The clinical and
laboratory information was documented using standardized
questionnaires of the Neuroviruses Emerging in the Americas
Study forms adapted from the International GBS Outcome
Study.3,11
The onset of GBS and disease nadir were defined as the first
day of neurologic symptoms and the most severe clinical
weakness, respectively. Pure motor GBS was defined as limb
weakness in the absence of sensory deficits at neurologic ex-
amination, and sensorimotor GBS was defined as presence of
both limb weakness and sensory deficits. Limb muscle
strength was evaluated using the Medical Research Council
(MRC) sum score.12 Severity was assessed according to the
modified Rankin Scale (mRS),13 the GBS Disability Score
(GBSDS),14 the modified Erasmus GBS Outcome Score
(mEGOS),15 and the Erasmus GBS Respiratory Insufficiency
Score at admission (EGRIS).16
Laboratory Testing
Hematologic and comprehensive metabolic assessments, in-
cluding among others sodium and potassium levels, liver and
kidney function tests, and HIV serology, were performed in all
patients at admission. For the investigation of infectious agents,
blood, CSF, oropharyngeal swabs, and stool samples were
tested at the Naval Medical Research Unit 6 in Lima, Peru.
Blood samples were assessed for arboviral infections including
ZIKV, dengue virus (DENV), and chikungunya virus
(CHIKV) using quantitative real time-PCR.17 Oropharyngeal
swabs were tested for 20 respiratory pathogens using a multi-
plexed PCR assay (BioFire Diagnostics, Salt Lake City, UT).
Stool swabs in Cary Blair medium were analyzed using a
multiplexed PCR assay for gastrointestinal pathogens (BioFire
Diagnostics), which included 22 pathogens associated with
gastroenteritis, such as Campylobacter species (jejuni, coli, and
upsaliensis), and Escherichia coli. Stool samples were cultured
for identification and characterization of E coli and C jejuni.18
Positive culture samples were further characterized using
multiplexed PCR assays for identification of C jejuni19 and
Penner types.19,20 C jejuni isolates from stool cultures were
sequenced using next-generation sequencing techniques, and
the genomic assemblies underwent genomic and phylogenetic
analysis based on the hypervariable lipo-oligosaccharide (LOS)
region. Phylogenetic analysis was based on 83 C jejuni genome
assemblies from the National Center for Biotechnology In-
formation (NCBI), which included all 16 genomes reported to
be associated with GBS in the NCBI metadata and 67 addi-
tional genomes selected to represent a wide range of the col-
lection locations, dates, and studies available (appendix e-1,
links.lww.com/NXI/A403). These 83 genomes, the C jejuni
reference genome (NCTC11168),21,22 and the 4 genomes of 4
C jejuni isolates assembled from the present study were used to
construct a phylogenic tree from the sequence of the
Glossary
CHIKV = chikungunya virus;DENV = dengue virus; EGRIS = Erasmus GBS Respiratory Insufficiency Score;GBS = Guillain-
Barré syndrome; GBSDS = Guillain-Barré syndrome Disability Score; HC = healthy control; HCH = Hospital Cayetano
Heredia; IQR = interquartile range; LOS = lipo-oligosaccharide; mEGOS = modified Erasmus GBS Outcome Score;MRC =
Medical Research Council; mRS = modified Rankin Scale; NCBI = National Center for Biotechnology Information; NCS =
nerve conduction study; PS = phosphatidylserine; ROC = receiver operating characteristic; ST = sequence type; ZIKV = Zika
virus.
2 Neurology: Neuroimmunology & Neuroinflammation | Volume 8, Number 2 | March 2021 Neurology.org/NN
hypervariable LOS biosynthesis gene locus using the
Nextstrain-Augur pipeline.23
To evaluate the association between C jejuni infection and
GBS, serum samples from 42 GBS cases were compared with
serum samples of 41 controls for the presence of anti–C jejuni
IgA, IgM, and IgG antibodies by ELISA following a case-
control methodology.24 Control samples were obtained from
subjects from the same or neighboring households of the
patients with GBS. The controls were evaluated by a neu-
rologist to exclude a history of weakness within the previous
year and to document normal neurologic status. The presence
of anti–C jejuni antibodies was expressed as a ratio of optical
density between a test sample and the cutoff serum sample. A
ratio > 1.0 for IgM or IgA was considered evidence of a recent
C jejuni infection. Concomitant C jejuni infection was defined
as a positive Campylobacter PCR in a stool sample or by stool
culture.
Case-control methodology was also used to study anti-
ganglioside immunity using a multiplexed array panel to
identify specific antiganglioside IgG antibodies. Patient and
control sera were screened on microarrays.25 Glycolipid
microarrays consisted of a panel of 16 single glycolipids, the
majority of which are gangliosides (GM1, GM2, phosphati-
dylserine [PS], GM4, GA1, GD1a, GD1b, GT1a, GT1b,
GQ1b, GD3, SGPG, LM1, GalNAc-GD1a, GalC, and sulfa-
tide) and 120 heteromeric 1:1 (v:v) complexes printed in
duplicate. The presence of antiglycolipid antibodies was de-
termined using human IgG isotype-specific, fluorescent-
Figure 1 Epidemiologic Profile of 2018–2019 Guillain-Barré Syndrome (GBS) Outbreaks in Peru
(A) Epidemiologic curves (2018–2019)
of GBS cases in Peru based on Peru-
vian Ministry of Health data.6 (B) Map
of Peru shows regions of origin of
GBS cases included in the study.
Cajamarca, Huaraz (Ancash), and
Huancavelica are cities located in the
highlands where no arbovirus trans-
mission was reported.
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conjugated secondary antibodies, and its intensity was mea-
sured on a scale of 0–65,535 using a Genepix 4300A (Mo-
lecular Devices, San Jose, CA) microarray scanner. Antibody
intensity values were reported as the average of duplicate
median fluorescent intensity values per sample. Results were
graphically displayed as heat maps using Pearson correlation
hierarchical clustering (MeV software). The optimal cutoff
value for antiglycolipid IgG antibodies, above baseline levels,
was calculated from receiver operating characteristic (ROC)
curves using Youden index.
Statistical Analysis
The clinical and laboratory findings were described using
absolute and relative frequencies. Median and interquartile
ranges (IQRs) were reported for quantitative variables. The
χ2 or Fisher exact test, OR, and 95% CIs were used to de-
termine differences between the groups. A p value <0.05 was
considered significant. Area under the curve was calculated for
each antiglycolipid antibody combination in ROC analysis.
Statistical analyses were performed using Stata software,
V15.0 (College-Station, TX).
Ethical Considerations
This study was reviewed and approved by the HCH In-
stitutional Review Board. All patients (or relatives when pa-
tients were incapacitated) and healthy controls (HCs)
provided written informed consent.
Data Availability
All data reported within the article are available anonymized
on reasonable request by qualified investigators.
Results
Clinical Features
Fifty-nine patients suspected of GBS were seen between May
and August 2019. Ten were excluded: 8 had insufficient data
due to transfer to other hospitals during the outbreak, 1 patient
had a recent infectionwithHIV, syphilis and tuberculosis, and 1
patient had only cranial nerve involvement. Of the 49 included
patients, 43 were from Lima city and 6 fromNorthern area and
highlands of Peru (figure 1B). The demographic and clinical
characteristics of the 49 patients are described in table 1. All
patients fulfilled Brighton criteria level 1 (84%) or level 2
(16%). The median age was 44 years (IQR 30–54 years), and
28 (57%) were male. Thirty-two patients (65%) had symptoms
of an infection 6 weeks preceding the onset of GBS: 24 (49%)
diarrhea and 13 (27%) upper respiratory tract symptoms, and 2
patients (4%) received an influenza vaccine. The median time
from onset of infectious to neurologic symptoms was 3 days
(IQR 2–9 days), and the time from onset of neurologic
symptoms to nadir was 6 days (IQR 3–7 days). At admission,
all patients reported limb weakness. Quadriparesis evolving in
less than 24 hours from neurologic symptom onset was ob-
served in 5 patients (10%). The median GBSDS at admission
was 4 (IQR 3–4), and EGRIS was 3 (IQR 2–4). Fifteen
patients (31%) had cranial neuropathy, with the facial nerve
most commonly involved. The medianMRC sum score was 42
(IQR 26–50). Most patients (80%) were classified clinically as
pure motor GBS. Neurologic examination, treatment, and
outcome at nadir and at 6-month follow-up are detailed in table
e-1 (links.lww.com/NXI/A406).
NCSs/EMG studies were performed in all patients at amedian of
16 days after onset of neurologic symptoms (IQR 10–23 days).
Twenty-one patients (43%) had axonal neuropathy (acutemotor
axonal neuropathy), 9 (18%) demyelinating neuropathy (acute
inflammatory demyelinating polyneuropathy), 8 (16%) equivo-
cal, 5 (10%) inexcitable, and 6 (12%) had normal studies.
Forty-seven patients (96%) received treatment with IVIg
(51%), plasmapheresis (18%), or both (27%). The standard
treatment was 5 sessions of plasmapheresis or 0.4 mg/kg/
d IVIg for 5 days. IVIg treatment was stopped in 1 patient who
developed angioedema during their second session and who
died before starting plasmapheresis. Two patients did not
receive treatment, 1 because of lack of treatment availability
on admission and 1 due to initial misdiagnosis. Both patients
improved without treatment. Thirteen patients (27%) were
admitted to the intensive care unit, 12 (24%) required ven-
tilatory support, and 6 (12%) had cardiac dysautonomia. The
median hospitalization time was 14 days (IQR 9–23 days).
One week after admission, the median mEGOS was 5 (IQR
2–9). Most patients improved as indicated by mRS score at
6-month follow-up (median 2, IQR 1–2) compared with
nadir (median 4, IQR 4–5). Four patients (8%) died. The
most common sequela after 6 months was neuropathic pain
(69%) (table e-1, links.lww.com/NXI/A406).
Laboratory Testing
Hematologic and biochemical testing at admission were
normal in all cases. CSF examination was performed in 48/49
patients at a median of 5 days (IQR 4–7 days) after start of
neurologic symptoms. All patients had normal cell counts
(median 0, IQR 0–1), and 14 (29%) had an increased protein
level (>52 mg/dL) (table 1).
Laboratory results for infectious agents and antiganglioside
profiles are described in table 2. One patient with known HIV
infection was HIV positive. Twenty (41%) patients un-
derwent testing for ZIKV, 26 (53%) for DENV, and 22 (45%)
for CHIKV, and all were negative. Nineteen patients (39%)
underwent testing by Film Array respiratory panel, and 5
(26%) were positive for common respiratory viruses not
known to be associated with GBS (table 2).
In 43 patients (88%), biosamples were available for C jejuni
infection testing with either molecular or serologic assays or
stool cultures (table e-2, links.lww.com/NXI/A407). In 23/
42 (55%) patients, anti-C jejuni IgM and/or IgA antibodies
were found, of whom 9 also tested positive for Campylobacter
sp PCR in stool. In contrast, only 11/41 (27%) controls had
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evidence of anti-C jejuni IgM or IgA (OR: 3.3, CI 95% 1.2–9.2,
p < 0.01) (table 2).
The PCR-based gastrointestinal panel showed that 14/37
(38%) patients had evidence of Campylobacter sp genome.
Stool cultures from 4 of these patients grew bacteria, which
were confirmed as C jejuni by immunologic and molecular
assays (table 2, table e-2, links.lww.com/NXI/A407). Penner
molecular typing indicated that these isolates were all HS41
capsule type. Genomic analysis showed that these strains were
clonal, sequence type (ST) ST2993, with class A LOS bio-
synthesis locus, a pathogenicity island that contains genes with
the potential to generate LOS that mimic human gangliosides.
Phylogenetic analysis showed that of the 20 GBS-associated C
jejuni genomes, 15, including the 4 isolates from this study, have
LOS regions fairly closely related to one another and to other
strains of C jejuni associated with GBS isolated in China and
Africa (figures 2 and 3). Sample collection regions do not
appear to define clades, with strains from countries with nu-
merous samples spread throughout the tree. All 4 C jejuni
isolates from our study had the Asn51 polymorphism at cstII
gene (figure e-1, links.lww.com/NXI/A404) based on the
alignments to ICDCCJ07001 indicating the capability to syn-
thesize both alpha 2–3 and alpha 2–8 sialic acid linkages on
their LOS core oligosaccharide.26,27 The genomes of these 4 C
jejuni isolates were deposited at NCBI within BioProject
PRJNA643291 (accession numbers SAMN15508151,
SAMN15508152, SAMN15508153, and SAMN15508154,
ncbi.nlm.nih.gov/bioproject/PRJNA643291).
Combining serologic assay and stool PCR, 28/43 patients
(65%) had evidence of recent C jejuni infection (table 2, table
e-2, links.lww.com/NXI/A407). Of interest, these 28 patients
did not significantly differ in the time to nadir, clinical variants,
or electrophysiologic subtypes to the 15 patients without
evidence of a recent C jejuni infection (table e-2). Patients
Table 1 Demographic and Clinical Characteristics of
Patients With GBS
Characteristics N = 49
Age, y 44
(30–54)
Male sex 28 (57)
General symptoms before the
onset of the GBS (last 6 wk)
32 (65)
Diarrheaa 24 (49)





Time from onset of infectious
symptoms to admission, db
7 (7–14)
Time from onset of infectious symptoms to GBS onset, db 3 (2–9)
Time from onset of GBS symptoms to admission, d 4 (3–6)
Time from onset of GBS symptoms to nadir, d 6 (3–7)
GBS Disability Score at admission 4 (3–4)
Erasmus GBS Respiratory Insufficiency Score at
admission
3 (2–4)
Admission to ICU 13 (27)
Mechanical ventilation 12 (24)
Autonomic dysfunction 6 (12)
Duration of hospitalization, d 14 (9–23)
Brighton criteria for GBS diagnosis
Level 1 41 (84)
Level 2 8 (16)
GBS clinical variant
Pure motor 39 (80)
Sensorimotor 6 (12)
Pharyngeal-cervical-brachial 2 (4)
Miller Fisher syndrome 1 (2)
Bickerstaff brainstem encephalitis 1 (2)
CSF analysis 48 (98)
Time from onset neurologic symptoms
to CSF sampling, d
5 (4–7)
White cell count, cells/mm3 0 (0–1)
Total protein, mg/dL 33
(16–58)
Increased protein levelc 14 (29)
Time from GBS symptom onset to EMG, d 16
(10–23)
Table 1 Demographic and Clinical Characteristics of
Patients With GBS (continued)
Characteristics N = 49






Abbreviations: AIDP = acute inflammatory demyelinating polyneuropathy;
AMAN = acute motor axonal neuropathy; GBS = Guillain-Barré syndrome;
ICU = intensive care unit; NCS = nerve conduction study.
Data are presented as n/N (%) or median (interquartile range).
a Six patients had both diarrhea and upper respiratory symptoms.
b Based on 32 patients with a history of preceding general symptoms.
c Increasedprotein level is defined as >52mg/dL. The percentage is based on
48 CSF samples.
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Table 2 Laboratory Studies






HIV (ELISA) 1/49 (2)
Respiratory FilmArray (oropharyngeal swab)b
Rhinovirus/enterovirus 3/19 (16)
Respiratory syncytial virus 1/19 (5)
Coronavirus OC43 1/19 (5)
Gastrointestinal FilmArray (stool)c 24/37 (65)d
Campylobacter spe 14/37 (38)
Escherichia coli 16/37 (43)
Stool culture 11/37 (30)f
Campylobacter jejuni HS41 4/37 (11)
E coli 10/37 (27)
B. Serologic Case-Control Studies
GBS, no. (%) Controls, no. (%) OR (p)
Campylobacter jejuni serology
Patients tested, no. (%) 42 (100) 41 (100) —
Anti–C jejuni IgG 42(100) 41 (100) —
Anti–C jejuni IgM or IgA 23 (55) 11 (27) 3.3 (0.01)
Anti–C jejuni IgM 19 (45) 11 (27) 2.3 (0.081)
Anti–C jejuni IgA 12 (29) 0 —
Antiganglioside profile
Patients tested, no. (%) 42 (100) 41 (100) —
GalNAc-GD1a-GBS cases 3 (7) 4 (10) 0.7 (0.668)
GM1-GBS cases 4 (10) 1 (2) 4.2 (0.175)
GM1:GT1a-GBS cases 14 (33) 4 (10) 4.6 (0.009)
GM1:PS-GBS cases 17 (40) 8 (20) 2.8 (0.037)
GT1a-GBS cases 4 (9) 1 (2) 4.2 (0.175)
Abbreviations: CHIKV= chikungunyavirus;GBS=Guillain-Barré syndrome;DENV= denguevirus; PS= phosphatidylserine;qRT= quantitative real time;ZIKV= Zikavirus.
Bold values in OR (p) column indicate statistical significance (p < 0.05).
a All samples were tested for DENV-1, DENV-2, DENV-3, and DENV-4.
b In addition to the listed pathogens detected by the respiratory array assay, other pathogens tested were found negative and those included Mycoplasma
pneumoniae, adenovirus, coronavirus HKU1, NL63, 229E, and OC43, human metapneumovirus, influenza A, A/H1, A/H3, and A/H1-2009, influenza B, para-
influenza virus 1, 2, 3, and 4, Bordetella pertussis, and Chlamydia pneumoniae.
c In addition to the C jejuni and E coli detected, testing for other bacteria, parasite, and viruses included in the assay were negative, which included bacteria:
Clostridium difficile (toxin A/B), Plesiomonas shigelloides, Salmonella, Yersinia enterocolitica, Vibrio (parahaemolyticus, vulnificus, and cholerae), Vibrio cholerae,
diarrheagenic E coli/Shigella, enteroaggregative E coli (EAEC), enteropathogenic E coli (EPEC), enterotoxigenic E coli (ETEC), Shiga-like toxin-producing E coli
(STEC), E coli O157, and Shigella/enteroinvasive E coli (EIEC). Parasites: cryptosporidium, Cyclospora cayetanensis, Entamoeba histolytica, and Giardia lamblia.
Viruses: adenovirus F 40/41, astrovirus, norovirus GI/GII, rotavirus A, and sapovirus (I, II, IV, and V).
d Six patients had coinfection of both Campylobacter sp and E coli.
e Campylobacter (jejuni, coli, and upsaliensis).
f Three patients had positive culture for both C jejuni HS41 and E coli.
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with evidence of a recent C jejuni infection had a higher
percentage of preceding gastrointestinal symptoms, although
this was not significant (43% vs 27%, p = 0.69). Other pre-
ceding infectious symptoms were also not significantly
different.
Antiganglioside IgG antibodies of differing specificities were
detected in a high proportion of cases compared with HCs
(figure e-2, links.lww.com/NXI/A405). Summarizing this
overview heatmap, 2 broad populations of IgG antibodies
were dominantly present in this cohort: those reactive with
GM1 alone or in complexes and those reactive with GT1a,
alone or in complexes (table 2, figure 4). A smaller number of
samples contained antibodies to GalNAc-GD1a alone or in
complexes. Antibodies to other gangliosides including GM2,
GD1b, GD1a, and GT1b and to myelin glycolipids including
SGPG, LM1 and GalC were either very infrequently or not
observed. Ganglioside antigens were probed as single
Figure 2 Phylogenetic Tree of Campylobacter jejuni Isolates in GBS
Phylogenetic tree built from the lipo-oligosaccharide region of 88 C jejuni species using the Nextstrain pipeline, colored by region. The 4 Peruvian strain
assemblies are indicated. The tree was built via alignment to the ICDCCJ07001 strain and then rooted by inferring ancestral states. GBS = Guillain-Barré
syndrome.
Figure 3 Phylogenetic Map of Campylobacter jejuni Isolates in Guillain-Barré Syndrome (GBS)
Map distribution of strains depicted in the phylogenetic tree. Strains are colored by region of collection, which was available for all but 2 genomes, the C jejuni
reference, NCTC11168, and 1GBS-associated strain, G1, which had no listed collection location. The size of the circles within countries on the associatedworld
map is proportional to how many samples are included from that country.
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molecules and when in heteromeric complex (1:1 ratio) with
one other ganglioside or lipid. This use of complexes is known
to enhance antiganglioside antibody signals in a proportion of
serum samples.28 To identify the enhanced binding intensities
resulting from complexes, samples were probed against GM1
and GT1a in complex with other lipids (figure 4A). Results
were then analyzed and displayed using ROC curve analysis in
which the true and false-positive rates are calculated at various
threshold settings to generate sensitivity and specificity data
for the assay. ROC data for the major targets are shown in
figure 4, B and C and figure e-2B and C. Using this approach,
GM1 ganglioside in a 1:1 heteromeric complex ratio with PS
or GT1a ganglioside proved to be the most significant di-
agnostic marker. When GM1 was in complex with PS, anti-
bodies to the GM1:PS complex returned a sensitivity 78.6%
and a specificity of 78.0% for GBS (figure e-2B). When GM1
was in complex with GT1a, antibodies to the GM1:GT1a
complex returned a sensitivity of 81.0% and a specificity of
80.5% for GBS (figure 4B). The enhancing effect, as man-
ifested by an increase in fluorescence intensity units, of GM1
in complex with GT1a vs either antigen alone is shown in
figure 4C. In contrast, the GM1:GalNAc-GD1a complex did
not enhance reactivity with either glycolipid alone (figure
e-2C). When selecting the GM1:PS and GT1a:GM1 complex
antigen targets as biomarkers of GBS, 92.9% of patients had
IgG antibodies to one or both of these glycolipid complexes
compared with 31.7% of HCs.
Discussion
In the aftermath of the ZIKV epidemic in Latin America, that
was associated with significant increases in the incidence of
GBS, 2 large seasonal outbreaks of GBS occurred in Peru in
2018 and 2019.6,29 Our study, describing a large cohort of
patients and controls during the 2019 GBS outbreak in Lima,
Peru, demonstrates that this outbreak was associated with C
jejuni infection, a diarrheal bacterium that is the most com-
mon trigger of GBS worldwide. As the outbreak of GBS in
2018 occurred in the same season and regions of the country
(figure 1B), this outbreak was likely related to C jejuni as well.
Because stricter public health measures were instituted in
Peru, after the first COVID-19 case in March 2020, GBS
incidence decreased to less than 0.27/100,000.6
Figure 4 Antiganglioside Antibody Binding Profile in Peruvian GBS Cases
Graphical displays of GBS and healthy control (HC) serum IgG antiganglioside antibody binding. (A) Heatmaps illustrating the IgG binding intensity to 3 single
glycolipids and 4 heteromeric complex antigen targets in GBS cases (uppermap, n = 42) and HC sera (lowermap, n = 41). Each horizontal row refers to the IgG
binding reactivity of an individual GBS or HC serum sample, and each vertical row refers to each of the 7 targets displayed. The rainbow bar denotes the
intensity scale of IgG binding from low (blue) to high (red) intensity. Two patterns of reactivity are greatly amplified by presenting glycolipids/lipids targets as
heteromeric complexes compared with binding to each target alone: GM1:GT1a complex (first column *) and GM1:PS complex (fourth column **). Note that
these 2 patterns of heteromeric complex reactivity do not substantially overlap within any 1 patient, being mutually exclusive. (B) An illustrative receiver
operating characteristic (ROC) curve comparing the sensitivity and specificity of GT1a and GM1 as single glycolipids with the GT1a:GM1 heteromeric complex.
The highest sensitivity (81%) and specificity (80.5%) are seenwith the GM1:GT1a complex. (C) IgG reactivity values of each individual patient are plotted for the
same 3 antigen targets (GM1, GT1a, and GM1:GT1a complex) subjected to ROC analysis in panel B. Greatly enhanced binding intensity to the GT1a:GM1
heteromeric complex compared with the sum of the single glycolipid antigens is present in most samples. GBS = Guillain-Barré syndrome; PS =
phosphatidylserine.
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We found evidence of recent C jejuni infection in 28/43 pa-
tients (65%), of whom 9 were positive for Campylobacter sp
PCR in stool. Other preceding infections previously associated
with GBS, includingMycoplasma pneumoniae, DENV, CHIKV,
and ZIKV, were negative in all tested cases. Recent C jejuni
infection was significantly more likely to occur in GBS cases
(23/42, 55%) compared with controls (11/41, 27%, OR: 3.3, p
< 0.01). Of interest, the proportion of controls with a recent C
jejuni infection was high (27%), which may be indicative of an
ongoing outbreak of C jejuni, although our study was not
designed to investigate this. This high percentage may also be
in part due to overmatching of cases and controls or a high
prevalence ofC jejuni in Peru, as has been indicated by previous
serosurveillance studies.30,31 Notably, the vast majority of C
jejuni infections, even when bearing ganglioside mimics in their
LOS, manifest as uncomplicated enteritis and are not associ-
ated with the development of GBS. Genomic analysis of C
jejuni isolates showed that they have closely related LOS re-
gions to one another and to previously described GBS-
associated C jejuni genomes from China and Africa reported in
the past 2 decades, suggesting that these strains were in-
troduced or reemergent infections from an endemic reservoir
rather than being new emergent strains.32–34
Besides the laboratory evidence, the clinical and electro-
physiologic profile is typical for C jejuni–associated GBS as
described in previous studies.9,35,36 The majority of cases had
a preceding diarrheal illness, followed by an early-onset, rap-
idly progressive pure motor axonal GBS. This profile is in
contrast to the clinical profile that has been reported in as-
sociation with ZIKV or COVID-19, where most patients have
facial palsy, sensory and motor deficits, and a demyelinating
electrophysiologic subtype.37,38
However, there was not a uniform relationship between C
jejuni serotype and clinical, electrodiagnostic, and anti-
ganglioside profile. This may be due tomethodological factors
that prevent unambiguous case definition and ascertainment.
For example, CSF examination and electrodiagnostic studies
are not always sensitive diagnostic tools in GBS, especially
when done early in the disease course. This may have resulted
in only 29% of patients having an increased protein level in
CSF, or inaccurate classification of electrophysiologic studies
as axonal or demyelinating.8,39 The time between onset of
systemic and neurologic symptoms (median 3 days, IQR 2–9
days) was also shorter than expected based on previous
studies, which may be due to the wide range of the incubation
period of C jejuni (1–10 days); patients only reporting
symptoms when they become severe; or the presence of a
parainfectious rather than postinfectious mechanism, as pre-
viously reported in ZIKV-related GBS.3,40 Another surprising
finding was the high percentage (27%) of cases with diarrhea
in the group without evidence of a recent C jejuni infection.
This may due to the presence of other infections able to
trigger GBS that may lead to gastrointestinal symptoms or low
sensitivity of the standard serologic testing method for recent
C jejuni infection (presence of IgM antibody) in a population
where the incidence of infection, as indicated by the univer-
sally positive IgG serology, is very high. Notwithstanding
previous studies that show diarrhea has been associated with a
poor prognosis, the percentage of our patients able to walk at
6 months was high (82%), although we did find that diarrhea
was more frequent (67% vs 45%) in patients with worse
outcome, as defined by mRS score ≥ 4 at 6 months.35,41
The antiganglioside antibody profile, with strong positivity for
GM1 and anti-GT1a, as single antigens or in complex, is
similar to what has previously been found in post–C jejuni
GBS in other parts of the world and lends strong support that
these patients represent the typical immune phenotype seen
inC jejuni–associatedGBS.42–44 The use of complexes of GM1
and GT1a with each other or other lipids (herein PS) greatly
enhanced the sensitivity of antibody detection in this cohort.
The significant presence and high frequency of antiganglio-
side antibodies lends strong evidence to the conclusion that
molecular mimicry between Campylobacter LOS and gangli-
osides is the immunopathologic driver of this form of GBS in
Peru. The high prevalence of anti-GT1a antibodies in this
groups is consistent with the cstII polymorphism (Asn51)
seen in this study and similar to that observed in a GBS
outbreak in China.45
The main limitation of our study is that we were not able to
perform complete laboratory studies in all patients and con-
trols as the study was conducted in the context of an emerging
outbreak. We were able to exclude other preceding infections,
including arboviruses, in 53% of cases and completed the
serologic case-control study in 86% of cases. It is unlikely that
different results would have been obtained had all subjects
been tested.
In conclusion, we showed that C jejuni, and not ZIKV as was
initially thought, was the infectious driver of the 2019 GBS
outbreak in Peru, and the clinical, electrophysiologic, and
immunologic profile was consistent with C jejuni–related
GBS. The C jejuni strains were likely introduced or ree-
mergent infections from an endemic reservoir and not new
emergent strains. This finding has global relevance as it in-
dicates that the C jejuni strains linked to GBS circulate widely
in different parts of the world. This shows that researchers
should remain aware of C jejuni as a trigger for GBS when
investigating the association between other infections, in-
cluding COVID-19, and GBS. Reinforcing public health
measures, including setting up campylobacteriosis and GBS
surveillance, to rapidly identify new epidemics, pathologic
strains, and sources of transmission should be encouraged to
prevent future outbreaks.30,31,46
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12. Kleyweg RP, van der Meché FGA, Schmitz PIM. Interobserver agreement in the
assessment of muscle strength Guillain-Barre syndrome. Muscle Nerv 1991;14:
1103–1109.
13. Van Swieten JC, Koudstaal PJ, Visser MC, Schouten H, Van Gijn J. Interobserver
agreement for the assessment of handicap in stroke patients. Stroke 1988;19:604–607.
14. Hughes RAC, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial of pred-
nisolone in acute polyneuropathy. Lancet 1978;312:750–753.
15. Walgaard C, Lingsma HF, Ruts L, Van Doorn PA, Steyerberg EW, Jacobs BC. Early
recognition of poor prognosis in Guillain-Barré syndrome. Neurology 2011;76:
968–975.
16. Walgaard C, Lingsma HF, Ruts L, et al. Prediction of respiratory insufficiency in
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Microbiol Infect 2007;13:915–922.
25. Halstead SK, Kalna G, Islam MB, et al. Microarray screening of Guillain-Barré syn-
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31. Kaakoush NO, Castaño-Rodŕıguez N, Mitchell HM, Man SM. Global epidemiology
of campylobacter infection. Clin Microbiol Rev 2015;28:687–720.
32. Zhang M, Li Q, He L, et al. Association study between an outbreak of Guillain-Barre
syndrome in Jilin, China, and preceding Campylobacter jejuni infection. Foodborne
Pathog Dis 2010;7:913–919.
33. Prendergast MM, Lastovica AJ, Moran AP. Lipopolysaccharides from Campylobacter
jejuni O:41 strains associated with Guillain-Barre syndrome exhibit mimicry of GM1
ganglioside. Infect Immun 1998;66:3649–3755.
34. Nachamkin I, Liu J, Li M, et al. Campylobacter jejuni from patients with Guillain-Barré
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